Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Volume 59, Number 5, September 10, 2002
Right arrow Supplementary Data
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bromberg, J. E.C.
Right arrow Articles by Taphoorn, M. J.B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bromberg, J. E.C.
Right arrow Articles by Taphoorn, M. J.B.
Related Collections
Right arrow All Imaging
Right arrow MRI
Right arrow All Oncology
Right arrow Primary brain tumor

Neurology 2002;59:762-764
© 2002 American Academy of Neurology
Brief Communications

Is a "vanishing tumor" always a lymphoma?

J. E.C. Bromberg, MD, M. D. Siemers, MD and M. J.B. Taphoorn, MD

From the Department of Neurology, University Medical Centre, Utrecht, the Netherlands.

Address correspondence and reprint requests to Dr. Jacoline E.C. Bromberg, Department of Neurology, University Medical Centre, PO Box 85500, 3508 GA Utrecht, the Netherlands; e-mail: J.E.C.Bromberg{at}neuro.azu.nl

The authors report clinical and radiologic characteristics and ultimate diagnosis in 12 patients with a regressing cerebral mass lesion. Primary CNS lymphoma (PCNL) was found in only half of the patients with such a lesion. In patients showing a complete resolution of the enhancing lesion the probability of finding a PCNL is smaller and survival is longer.




This article has been cited by other articles:


Home page
 NeurologyHome page
J. O. Fleming, B. M. Keegan, and J. E. Parisi
A 52-year-old man with progressive left-sided weakness and white matter disease
Neurology, August 7, 2007; 69(6): 600 - 606.
[Full Text] [PDF]

Home page
 Neuro OncologyHome page
P. Kiewe, C. Loddenkemper, I. Anagnostopoulos, M. Reinwald, E. Thiel, and A. Korfel
High-dose methotrexate is beneficial in parenchymal brain masses of uncertain origin suspicious for primary CNS lymphoma
Neuro Oncology, April 1, 2007; 9(2): 96 - 102.
[Abstract] [Full Text] [PDF]